Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data

• मुख्य लेखकों: Ekaterina Alexeeva (लेखक), Elizaveta Krekhova (लेखक), Tatyana Dvoryakovskaya (लेखक), Ksenia Isaeva (लेखक), Aleksandra Chomakhidze (लेखक), Evgeniya Chistyakova (लेखक), Olga Lomakina (लेखक), Rina Denisova (लेखक), Anna Mamutova (लेखक), Anna Fetisova (लेखक), Marina Gautier (लेखक), Dariya Vankova (लेखक), Ivan Kriulin (लेखक), Ruslan Saygitov (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

BackgroundA significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack of efficacy or safety concerns. Studies of biologic therapy switch regimens in sJIA are required.MethodsPatients with sJIA who swi...